Annotation Detail

Information
Associated Genes
ERBB2
Associated Variants
ERBB2 SERUM LEVELS
ERBB2 SERUM LEVELS
Associated Disease
breast cancer
Source Database
CIViC Evidence
Description
Serum and tissue levels of HER2 (ERBB2) were analyzed in 1,902 breast cancer patients treated with lapatinib or control. Serum HER2 (sHER2) levels measured by ELISA were higher in patients with HER2 amplification (median sHER2 levels were 25.1 ng/mL in patients with HER2-positive tumors). Serum HER2 levels were Independent predictors of lapatinib progression free survival benefit (HR per 10-ng/mL increase in serum HER2: lapatinib-containing therapies, 1.009 v nonlapatinib-containing therapies, 1.044; P interaction < .001). Tissue HER2 levels were also predictive, but within this subgroup, serum HER2 still independently predicted lapatinib PFS benefit.
Variant Origin
N/A
Variant Origin
N/A
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/972
Gene URL
https://civic.genome.wustl.edu/links/genes/20
Variant URL
https://civic.genome.wustl.edu/links/variants/416
Rating
4
Evidence Type
Predictive
Disease
Breast Cancer
Evidence Direction
Supports
Drug
Lapatinib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
26811533
Drugs
Drug NameSensitivitySupported
LapatinibSensitivitytrue